![Send email](https://curamus-cancer.fr/wp-content/themes/curamus/assets/icones/mail-2-little.svg")
Instabilité des microsatellites et cancer
Coordonné par le Pr Alex Duval et le Dr Florence Renaud
Les cancers avec instabilité des séquences répétées microsatellites de l’ADN (MSI) constituent une famille de tumeurs fréquentes, associées à de nombreuses localisations (côlon, estomac, endomètre, pancréas, prostate, poumon, sein, ovaire, cerveau,…). Les principaux objectifs de ce programme, dédiés aux cancers MSI de toutes localisations, sont :
- De comprendre les processus qui sous-tendent l’initiation et la progression tumorale MSI et façonnent le microenvironnement de ces cancers.
- De développer de nouveaux outils diagnostiques et schémas thérapeutiques adaptés à leur prise en charge moderne par une médecine de précision en pleine émergence (immunothérapie, inhibiteurs des checkpoints immunitaires).
Synthèse grand public et actualités
🎞 Vidéo : Le projet Predy-Lynch
Nous avons échangé avec le Pr Patrick Benusiglio, le Pr Alex Duval et l’équipe de la start-up MSInsight autour du […]
🎞 Vidéo : au coeur de la tumeur MSI, mieux connaître pour mieux combattre
Les tumeurs MSI (pour Instabilité des MicroSatellites), sont une catégorie de tumeurs qui possèdent des altérations génomiques dûes à un […]
ASCO 2020 – Session plénière – Pr Thierry André
Congrès Annuel de l’ASCO – Session plénière – Pr Thierry André Le congrès de l’American Society of Clinical Oncology (ASCO) […]
Pembrolizumab dans le cancer colorectal de stade IV MSI-H – KEYNOTE-164 (NCT02460198)
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164 Le DT, Kim TW, Van […]
Traitements des cancers MSI gastro-intestinaux par immuno-oncologie
How to Improve the Results With IO Agents in MSI GI Cancer? https://oncologypro.esmo.org/content/download/231632/3918938/version/1/file/WORLDGI2019_76_andre.pdf
[ESMO 2019] L’efficacité des inhibiteurs de PD-1 confirmée dans le traitement des tumeurs « MSI »
L’analyse poolée de deux études KEYNOTE-164 et KEYNOTE-168, à laquelle le Pr Thierry André, chef du service d’oncologie digestive de […]
Publications
Articles originaux
2025
- Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study. . Depotte et al. J Immunother Cancer. 2025 May.
- Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study. André et al. Ann Oncol. 2025 Mar.
- Pathogenic germline variants in patients with early-onset colorectal cancer according to phenotype. . Dardenne et al. Eur J Hum Genet. 2025 Jun.
2024
- Microsatellite instability at U2AF-binding polypyrimidic tract sites perturbs alternative splicing during colorectal cancer initiation. . Jonchère et al. Genome Biol. 2024 Aug.
- Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.. Cohen et al. Eur J Cancer. 2024 Aug.
- Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation. . Cohen et al. Eur J Cancer. 2024 Mar.
- Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer. . André et al. N Engl J Med. 2024 Nov.
- A right atrial mass and colonic cancer in a patient with Lynch.. Ederhy et al. Lancet. 2024 May.
- Pembrolizumab Versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase 3 KEYNOTE-177 study. . André et al. Ann Oncol. 2024 Nov.
- Survival Outcomes in Patients with Monobloc-Resected Stage IIC (pT4bN0) Colon Cancer: A Retrospective Observational Cohort Study. . Logeart et al. Clin Colorectal Cancer. 2024 Dec.
- Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer.. Ambrosini et al. Ann Oncol. 2024 Jul.
2023
- Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability.. Ratovomanana et al. Ann Oncol. 2023 Aug.
- Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With Glioma.. Benusiglio et al. JCO Precis Oncol. 2023 May.
- BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors.. Colle et al. Oncologist. 2023 Sep.
- RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status.. Dorard et al. Oncogene. 2023 May.
2022
- Consequences of the Hsp110DE9 mutation in tumorigenesis and the 5-fluorouracil-based chemotherapy response in Msh2-deficient mice. Noel et al. Cell Mol Life Sci. 2022 Jun.
- Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. André et al. J Clin Oncol. 2022 Aug.
- Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. André et al. Ann Oncol. 2022 Jun.
Revues
2022
- The Role of Immunohistochemistry Markers in Endometrial Cancer with Mismatch Repair Deficiency: A Systematic Review. Favier et al. Cancers (Basel). 2022 Aug.
2021
- Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency. Cohen et al. Cancers (Basel). 2021 Mar.
2019
- Microsatellite instability and cancer: from genomic instability to personalized medicine. Collura et al. Med Sci (Paris). 2019 Jun-Jul.